BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer

Francesca De Santis(Fondazione IRCCS Istituto Nazionale dei Tumori), Massimo Di Nicola(Fondazione IRCCS Istituto Nazionale dei Tumori)

Cellular Oncology

March 31, 2022

10.1007/s13402-022-00663-y

Cited by 22

Related Papers

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

|Journal of Clinical Oncology|2010|167

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study

|International Journal of Radiation Oncology*Biology*Physics|2015|48

Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia

|Cancer|2011|28

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM

|Journal of Clinical Oncology|2013|14

Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.

|Blood|2009|1